Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort
Hyperglycemia triggers pathological pathways leading to fibrosis, where extracellular matrix (ECM) components are accumulated. We investigated the potential of endotrophin, a pro-fibrotic molecule generated during collagen type VI formation, as a risk marker for complications to type 1 diabetes. End...
Saved in:
| Published in: | Frontiers in molecular biosciences Vol. 10; p. 1229579 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Frontiers Media S.A
01.09.2023
|
| Subjects: | |
| ISSN: | 2296-889X, 2296-889X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hyperglycemia triggers pathological pathways leading to fibrosis, where extracellular matrix (ECM) components are accumulated. We investigated the potential of endotrophin, a pro-fibrotic molecule generated during collagen type VI formation, as a risk marker for complications to type 1 diabetes. Endotrophin was measured in serum and urine from 1,468 persons with type 1 diabetes. Outcomes included a composite kidney endpoint, first major adverse cardiovascular event (MACE), all-cause mortality, progression of albuminuria, incident heart failure, and sight-threatening diabetic eye disease. Cox proportional hazards models adjusted for conventional risk factors were applied. A doubling of serum endotrophin was independently associated with the kidney endpoint (
n
= 30/1,462; hazard ratio 3.39 [95% CI: 1.98–5.82]), all-cause mortality (
n
= 93/1,468; 1.44 [1.03–2.0]), and progression of albuminuria (
n
= 80/1,359; 1.82 [1.32–2.52]), but not with first MACE, heart failure, or sight-threatening diabetic eye disease after adjustment. Urinary endotrophin was not associated with any outcome after adjustment. Serum endotrophin was a risk marker for mortality and kidney complications in type 1 diabetes. Biomarkers of ECM remodeling, such as serum endotrophin, may identify persons with active pro-fibrotic processes at risk for complications in diabetes and where antifibrotic agents may reduce this risk. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Arkadeep Mitra, City College, Kolkata, India Trisha Bansal, University of Illinois Chicago, United States Reviewed by: Dinesh Yadav, University of Alabama at Birmingham, United States |
| ISSN: | 2296-889X 2296-889X |
| DOI: | 10.3389/fmolb.2023.1229579 |